23 November 2023
23 November 2023
Mesoblast has faced several setbacks from the FDA over the last few years for its cell therapy Ryoncil to treat SR-aGvHD.
The fast track designation for the paediatric multi-food allergy therapy ADP101 was based on the Phase I/II data.
The data from the Phase II trial showed more than a 5% drop in weight in 57.1% of type 2 diabetes patients treated with 6mg of mazdutide.
Landos’s small molecule drug candidate NX-13 is currently in Phase II clinical trials with topline results expected in Q4 2024.
BerGenBio plans to initiate the second part of the trial with bemcentinib in early 2024, with initial data expected later in the year.
The funding will go towards the development of Alto Neuroscience's four CNS candidates, with Phase II study data readouts expected by early 2025.
Pfizer and BioNTech countersued Moderna following an initial August 2022 suit alleging that its patents were overly broad.
The Queensland and Australian governments, as well as various partners, supported the trial of the re-engineered molecular clamp.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
